Industry: Cannabis

Cannabis funding and investors

Growers, dispensaries and multi-state operators now raise mostly from lenders and property buyers, not venture funds. We prepare the deck, model and lender materials that hold up in their credit reviews.

  • Equity, loans and sale-leasebacks, compared for your licences and states
  • Decks and models that show cash flow after 280E and debt service
  • Waveup prepares investor materials for cannabis companies: $3B+ raised for 600+ startups since 2014

In short

What is cannabis funding?

Cannabis funding is the money licensed growers, dispensaries and multi-state operators raise to build, buy and refinance. Most of it is debt: loans, notes and sale-leasebacks of their buildings. Debt made up 61% of the cannabis deal value Viridian tracked from January to September 2026. Equity is scarce, so lenders set the terms.

Who it's for
Cultivators, dispensaries, multi-state operators and ancillary companies, pre-seed to Series D+
What we build
Investor and lender deck, financial model, valuation, investor list, data room
Track record
$3B+ raised for 600+ startups since 2014

Market data checked on 6 November 2026. Sources are under each section.

Why is the cannabis industry struggling to raise money?

Prices keep falling in older markets, and adult-use sellers still can't deduct normal costs for federal tax. Yet operators with steady cash flow still find lenders and property buyers.

The opportunity

Federal rules began to shift in 2026, and consolidators are buying licensed stores.

  • Medical marijuana under a state licence moved to Schedule III in April 2026
  • Consolidators are buying stores, paying with shares and seller notes
  • REITs and private lenders still fund operators with steady cash flow

The problem

Equity has nearly dried up: cannabis companies raised $142M of it from January to September 2026. Lenders fill the gap, and they want security, covenants and steady cash flow.

Market size

How much cannabis do licensed US stores sell, and what's changing?

Licensed US stores sold about $27 billion of cannabis in 2025, by The Marijuana Herald's tally of state reports. Four shifts decide who gets funded next:

  • Rescheduling: state-licensed medical marijuana entered Schedule III on 28 April 2026, and a wider DEA decision is pending
  • Price pressure: adult-use flower in Michigan averaged $61.91 an ounce at retail in October 2025
  • Consolidation: Cresco Labs agreed to buy nine PharmaCann stores in Pennsylvania in 2026
  • New taxes: Michigan added a 24% wholesale tax on adult-use marijuana from 1 January 2026
Legal cannabis sales in Colorado: $995.6M in 2015, a peak of $2.23B in 2021, and $1.32B in 2025.

Cannabis in 2026, in six numbers

$2.3B

sold in licensed US cannabis stores in December 2025 alone

850

adult-use retail licences were active in Michigan in October 2025

41,359

people worked in Michigan's licensed cannabis businesses in October 2025

$3.26B

in marijuana taxes collected by Colorado from 2014 to August 2026

88,326

suspicious activity reports filed on marijuana businesses in 2024

40

states, plus DC, run regulated medical marijuana programs (December 2025)

Venture capital

Where does cannabis capital come from in 2026?

Cannabis deal value rose in 2026, but most of it was debt and M&A rather than new equity. Deals also got smaller as the year went on.

Cannabis capital raised from January to September 2026: about $1.90B in debt and $142M in equity, by Viridian's count.
$3.10B

in cannabis debt, equity and M&A deals from January to September 2026

~$12M

average cannabis deal in Q3 2026, down from about $41M in Q1

28

M&A deals in Q3 2026, the most common deal type that quarter

Who invests in cannabis companies?

A cannabis-led equity investor, specialist lenders and sale-leaseback REITs, with a few names for each. Equity is the scarcest of the three.

Investor
Type and base
Cannabis companies backed
Stage or cheque
KEY Investment Partners
Cannabis-led investor since 2018, Denver
PharmaCann, Garden Club, Highway Cannabis Co.
Not stated; operators, software, ag tech and specialty finance
Chicago Atlantic
Senior secured lender, Chicago
Verano (a featured deal)
Featured facilities of $96.5M and $350M for cannabis operators
FundCanna
Working-capital lender, cannabis only
Tradecraft Farms ($3.2M bridge financing)
Credit lines, working capital, equipment loans
XS Financial
Equipment lender, Los Angeles
Curaleaf, Ayr, Columbia Care
$1M to $75M+ per financing
Innovative Industrial Properties
Sale-leaseback REIT, San Diego
37 tenants in 108 properties across 19 states (Sep 2026)
Long-term net leases; $2.4B invested
NewLake Capital Partners
Sale-leaseback REIT, founded 2019
Curaleaf and Cannabist sites; 1.7M sq ft, 100% leased
Sale-leasebacks, purchases and build-to-suit

Investor database

Pharma investors in our database

The funds with the most pharma investments. Pick a stage, or open a fund for its cheque sizes.

Top 5 by pharma investments

  • Investments by industry

    • Healthtech & Wellness42%
    • Pharma19%
    • Biotech17%
    Rounds
    Pre-seedSeed
    Average cheque
    Not listed
    Based in
    Los Angeles, California, United States

    28 investments in total, 7 tagged Pharma.Open the full fund profile

  • Investments by industry

    • Healthtech & Wellness40%
    • Software & Apps15%
    • Pharma7%
    Rounds
    Pre-seedSeedSeries ASeries BSeries C+
    Average cheque
    Not listed
    Based in
    Dallas, United States
    Invests in
    USA

    88 investments in total, 7 tagged Pharma.Open the full fund profile

  • Investments by industry

    • Healthtech & Wellness49%
    • Biotech20%
    • Pharma14%
    Rounds
    SeedSeries A
    Average cheque
    Not listed
    Based in
    Toronto, Ontario, Canada

    25 investments in total, 5 tagged Pharma.Open the full fund profile

  • Investments by industry

    • Biotech21%
    • Healthtech & Wellness19%
    • Hardware. Robotics & IoT17%
    • Pharma7%
    Rounds
    SeedSeries ASeries BSeries C+
    Average cheque
    $1M–$3M$3M–$10M
    Based in
    Jackson, United States
    Invests in
    USA

    62 investments in total, 3 tagged Pharma.Open the full fund profile

  • Investments by industry

    • Healthtech & Wellness50%
    • Biotech19%
    • Pharma6%
    Rounds
    Seed
    Average cheque
    Not listed
    Based in
    San Francisco, United States
    Invests in
    Europe, USA, Canada

    33 investments in total, 2 tagged Pharma.Open the full fund profile

From our investor database.

Where do cannabis raises get stuck?

We interviewed 56 VCs for our Fundraising 2025 study. Their top reasons to pass were revenue growth, unit economics, burn and missed milestones. Defensibility and crowded categories came next. Cannabis lenders and investors start with four questions of their own.

Federal tax on adult-use sales

Adult-use marijuana is still in Schedule I, so section 280E still blocks normal deductions on those sales. For registered medical licensees, the April 2026 rule says 280E no longer applies.

What investors ask

  • What's your cash tax bill on adult-use sales, and on medical sales since April 2026?

What your deck shows

  • Cash taxes by line of business, before and after rescheduling
  • Any open tax positions, and what you've reserved for them

Banks that won't lend

FinCEN counted 507 banks serving marijuana businesses at the end of 2024. Few make large loans, so operators borrow from private lenders on tighter terms.

What investors ask

  • Who lends to you today, at what rate, and when does it mature?

What your deck shows

  • A debt schedule with rates, covenants and maturities
  • Cash flow that covers interest, with room to spare

Prices that keep falling

Colorado's legal cannabis sales in 2025 were 41% below their 2021 peak. Older markets reward low-cost growers and well-placed stores.

What investors ask

  • What's your margin if wholesale prices drop again next year?

What your deck shows

  • Cost per pound against today's wholesale price
  • Sales per store and average basket, month by month

Debt that comes due

In 2026, lender SNDL foreclosed on Parallel's stores, extinguishing about $842M of debt. Lenders take control when cash flow can't carry the loans.

What investors ask

  • How will you refinance before your notes mature?

What your deck shows

  • A maturity schedule and the cash flow that meets it
  • Owned property that could fund a sale-leaseback

How we help you raise

Flat fees agreed before we start. No success fee on advisory work.

Who we are

Waveup is a London-based fundraising and growth advisory, working in 60+ countries and 90+ industries. Since 2014 we have built the decks, models, CIMs and valuations behind $3B+ raised for 600+ startups.

About us
Track record
$3B+
raised for 600+ startups
Decks
1,000+
decks since 2014
M&A
50+
M&A transactions supported, including 20+ exits
Reach
60+
countries, across 90+ industries

Cannabis funding FAQ

How do cannabis businesses get funding?
Most start with founders' savings, friends and private investors. Once revenue is steady, operators borrow from specialist lenders, secured on property, equipment or receivables. Owners of buildings can sell them to a REIT and lease them back. Equity funds still exist, but they back few companies: cannabis equity raised came to $142M from January to September 2026.
Who are the biggest cannabis investors?
Can a cannabis business get a bank loan?
What is a cannabis sale-leaseback?
What does rescheduling mean for cannabis funding?
How much does help with a cannabis raise cost?

Raising for a cannabis company?

Tell us your states, licences and how much you need. We'll map the lenders and investors who fit, and what each will check.

Have a project in mind?

Leave your information below and one of our experts will be in touch to schedule a call.

Your name:
*Your email:
*You need help with:
Your project is:
Your current stage:
Your maximum budget:
How did you find us?